rofecoxib has been researched along with Edema in 41 studies
Edema: Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This safety study compared the GI tolerability, the blood pressure (BP) profile and the incidence of oedema with lumiracoxib and rofecoxib in the treatment of OA." | 9.13 | A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients. ( Krammer, G; Stricker, K; Yu, S, 2008) |
| " This study evaluated the effects of celecoxib 200 mg/day and rofecoxib 25 mg/day on blood pressure (BP) and edema in a 6-week, randomized, parallel-group, double-blind study in patients > or =65 years of age with osteoarthritis who were treated with fixed antihypertensive regimens." | 9.10 | Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. ( Bello, AE; Fort, JG; Puma, JA; Whelton, A; White, WB, 2002) |
| " Recently, head-to-head, randomized, controlled trials have shown a significantly higher incidence of blood pressure (BP) destabilization and clinically significant edema with rofecoxib than with celecoxib among older, hypertensive patients with osteoarthritis (OA)." | 7.72 | A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population. ( Becker, RV; Burke, TA; McCoy, MA; Trotter, JP, 2003) |
| "To investigate the relationship between nonselective nonsteroidal antiinflammatory drugs (NS NSAID), rofecoxib, celecoxib, and risk of edema and blood pressure destabilization in patients with rheumatoid arthritis (RA) and osteoarthritis (OA) receiving ordinary clinic care." | 7.72 | Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. ( Pettitt, D; Wolfe, F; Zhao, S, 2004) |
| "This study evaluates the action of celecoxib and rofecoxib, two selective cyclooxygenase-2 (COX-2) inhibitors in two acute models of inflammation, carrageenan (Cg)-induced rat pleurisy, and paw oedema formation." | 7.71 | Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation. ( Calixto, JB; Pinheiro, RM, 2002) |
| " Rofecoxib, an agent that selectively inhibits COX-2, has been shown to provide equivalent anti-inflammatory and analgesic efficacy to comparator non-selective NSAIDs in osteoarthritis (OA) and other pain models with a significant improvement in gastrointestinal (GI) safety and tolerability." | 7.71 | A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents. ( Bolognese, JA; Gertz, BJ; Krupa, D; Reicin, A; Sperling, RS, 2002) |
| " This safety study compared the GI tolerability, the blood pressure (BP) profile and the incidence of oedema with lumiracoxib and rofecoxib in the treatment of OA." | 5.13 | A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients. ( Krammer, G; Stricker, K; Yu, S, 2008) |
| "A phase II trial was initiated to analyze the activity of continuously administered pioglitazone and rofecoxib combined with low-dose chemotherapy (capecitabine or temozolomide) in patients with high-grade gliomas (glioblastoma or anaplastic glioma)." | 5.12 | Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study. ( Baumgart, U; Bogdahn, U; Hau, P; Hirschmann, B; Kunz-Schughart, L; Muhleisen, H; Reichle, A; Ruemmele, P; Steinbrecher, A; Weimann, E, 2007) |
| " This study evaluated the effects of celecoxib 200 mg/day and rofecoxib 25 mg/day on blood pressure (BP) and edema in a 6-week, randomized, parallel-group, double-blind study in patients > or =65 years of age with osteoarthritis who were treated with fixed antihypertensive regimens." | 5.10 | Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. ( Bello, AE; Fort, JG; Puma, JA; Whelton, A; White, WB, 2002) |
| " The compounds were evaluated for their anti-inflammatory activity in carrageenan induced rat paw edema model taking rofecoxib and indomethacin as standard drugs." | 3.85 | Synthesis of methanesulphonamido-benzimidazole derivatives as gastro-sparing antiinflammatory agents with antioxidant effect. ( Bali, A; Chaudhari, BB; Sharma, R, 2017) |
| "A series of 3-alkoxy-4-methanesulfonamido acetophenone derivatives were synthesized and evaluated for their anti-inflammatory activity in carrageenan-induced rat paw edema model." | 3.78 | Synthesis, evaluation and docking studies on 3-alkoxy-4-methanesulfonamido acetophenone derivatives as non ulcerogenic anti-inflammatory agents. ( Bali, A; Deb, PK; Ohri, R, 2012) |
| "Substituted thiazoles with different structural features were synthesized and screened for their anti-inflammatory activity in acute carrageenin induced rat paw edema model and chronic formalin induced rat paw edema model." | 3.74 | 2-Amino-5-thiazolyl motif: a novel scaffold for designing anti-inflammatory agents of diverse structures. ( Franklin, PX; Nivsarkar, M; Padh, H; Pillai, AD; Rathod, PD; Sudarsanam, V; Vasu, KK; Yerande, S, 2008) |
| "0032 muM) and COX-2 selectivity (SI > 120 000), 14s exhibited moderate antiinflammatory activity compared to celecoxib in a carrageenan-induced rat paw edema assay." | 3.72 | Design, synthesis, and biological evaluation of 6-substituted-3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors. ( Amini, M; Habeeb, AG; Knaus, EE; Li, H; Praveen Rao, PN, 2003) |
| " Recently, head-to-head, randomized, controlled trials have shown a significantly higher incidence of blood pressure (BP) destabilization and clinically significant edema with rofecoxib than with celecoxib among older, hypertensive patients with osteoarthritis (OA)." | 3.72 | A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population. ( Becker, RV; Burke, TA; McCoy, MA; Trotter, JP, 2003) |
| "The anti-inflammatory activity of fluoxetine, a selective serotonin reuptake inhibitor (SSRI), was studied on the carrageenan-induced paw inflammation in the rat." | 3.72 | Studies on the anti-inflammatory effect of fluoxetine in the rat. ( Abdel-Salam, OM; Arbid, MS; Baiuomy, AR, 2004) |
| "To investigate the relationship between nonselective nonsteroidal antiinflammatory drugs (NS NSAID), rofecoxib, celecoxib, and risk of edema and blood pressure destabilization in patients with rheumatoid arthritis (RA) and osteoarthritis (OA) receiving ordinary clinic care." | 3.72 | Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. ( Pettitt, D; Wolfe, F; Zhao, S, 2004) |
| "The aim of this study was to describe physician-reported management of clinically significant edema and/or destabilized blood pressure in patients with osteoarthritis (OA) and hypertension when initiating therapy with rofecoxib or celecoxib." | 3.71 | Physician-reported management of edema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension. ( Bristol, S; Burke, TA; May, C; Osterhaus, JT; Wentworth, C; Whelton, A, 2002) |
| "This study evaluates the action of celecoxib and rofecoxib, two selective cyclooxygenase-2 (COX-2) inhibitors in two acute models of inflammation, carrageenan (Cg)-induced rat pleurisy, and paw oedema formation." | 3.71 | Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation. ( Calixto, JB; Pinheiro, RM, 2002) |
| " Rofecoxib, an agent that selectively inhibits COX-2, has been shown to provide equivalent anti-inflammatory and analgesic efficacy to comparator non-selective NSAIDs in osteoarthritis (OA) and other pain models with a significant improvement in gastrointestinal (GI) safety and tolerability." | 3.71 | A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents. ( Bolognese, JA; Gertz, BJ; Krupa, D; Reicin, A; Sperling, RS, 2002) |
| "Treatment with indomethacin (2 mg/kg), rofecoxib, (10 mg/kg), or dexamethasone (2 mg/kg) significantly reduced the BaV- and BjV-induced oedema formation." | 1.34 | Role of cyclooxygenases in oedema-forming activity of bothropic venoms. ( Gutierrez, JM; Olivo, Rdo A; Teixeira, CF; Wallace, JL; Zamuner, SR, 2007) |
| "Rofecoxib is a poorly water soluble nonsteroidal anti-inflammatory drug with a poor dissolution profile." | 1.33 | Characteristics of rofecoxib-polyethylene glycol 4000 solid dispersions and tablets based on solid dispersions. ( Desai, KG; Liu, C, 2005) |
| "To determine the prevalence of chronic use of rofecoxib 50 mg." | 1.32 | High frequency of use of rofecoxib at greater than recommended doses: cause for concern. ( Arbogast, PG; Daugherty, JR; Graham, DJ; Griffin, MR; Ray, WA; Stein, CM, 2004) |
| "Acute inflammation was induced by sub-plantar injection of carrageenan (1%) in the rat hind paw." | 1.31 | Studies on the anti-inflammatory and anti-nociceptive effects of melatonin in the rat. ( Abdel-Salam, OM; Arbid, MS; Baiuomy, AR; El-Batran, S; El-Shenawy, SM, 2002) |
| "2." | 1.31 | Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation. ( Bakhle, YS; Chaves, CT; Ferreira-Alves, DL; Francischi, JN; Lima, AS; Moura, AC; Rocha, OA, 2002) |
| " Both exhibit good oral bioavailability and are potent in standard models of pain, fever, and inflammation yet have a much reduced effect on the GI integrity of rats compared to standard nonsteroidal antiflammatory drugs." | 1.30 | 2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors. ( Black, WC; Brideau, C; Chan, CC; Charleson, S; Chauret, N; Claveau, D; Ethier, D; Gordon, R; Greig, G; Guay, J; Hughes, G; Jolicoeur, P; Leblanc, Y; Nicoll-Griffith, D; Ouimet, N; Prasit, P; Riendeau, D; Visco, D; Wang, Z; Xu, L, 1999) |
| "Rofecoxib is a potent inhibitor of the COX-2-dependent production of PGE(2) in human osteosarcoma cells (IC(50) = 26 +/- 10 nM) and Chinese hamster ovary cells expressing human COX-2 (IC(50) = 18 +/- 7 nM) with a 1000-fold selectivity for the inhibition of COX-2 compared with the inhibition of COX-1 activity (IC(50) > 50 microM in U937 cells and IC(50) > 15 microM in Chinese hamster ovary cells expressing human COX-1)." | 1.30 | Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. ( Boyce, S; Brideau, C; Chan, CC; Charleson, S; Cromlish, W; Ethier, D; Evans, J; Ford-Hutchinson, AW; Forrest, MJ; Gauthier, JY; Gordon, R; Gresser, M; Guay, J; Kargman, S; Kennedy, B; Leblanc, Y; Leger, S; Mancini, J; O'Neill, GP; Ouellet, M; Patrick, D; Percival, MD; Perrier, H; Prasit, P; Rodger, I, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (7.32) | 18.2507 |
| 2000's | 33 (80.49) | 29.6817 |
| 2010's | 5 (12.20) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Black, WC | 2 |
| Brideau, C | 3 |
| Chan, CC | 3 |
| Charleson, S | 3 |
| Chauret, N | 1 |
| Claveau, D | 1 |
| Ethier, D | 2 |
| Gordon, R | 3 |
| Greig, G | 1 |
| Guay, J | 2 |
| Hughes, G | 2 |
| Jolicoeur, P | 1 |
| Leblanc, Y | 2 |
| Nicoll-Griffith, D | 1 |
| Ouimet, N | 1 |
| Riendeau, D | 2 |
| Visco, D | 1 |
| Wang, Z | 2 |
| Xu, L | 1 |
| Prasit, P | 3 |
| Shin, SS | 2 |
| Noh, MS | 2 |
| Byun, YJ | 1 |
| Choi, JK | 2 |
| Kim, JY | 2 |
| Lim, KM | 2 |
| Ha, JY | 1 |
| Kim, JK | 2 |
| Lee, CH | 1 |
| Chung, S | 2 |
| Cromlish, W | 2 |
| Grimm, EL | 1 |
| Leger, S | 2 |
| Li, CS | 1 |
| Thérien, M | 1 |
| Xu, LJ | 1 |
| Pal, M | 1 |
| Madan, M | 1 |
| Padakanti, S | 1 |
| Pattabiraman, VR | 1 |
| Kalleda, S | 1 |
| Vanguri, A | 1 |
| Mullangi, R | 1 |
| Mamidi, NV | 1 |
| Casturi, SR | 1 |
| Malde, A | 1 |
| Gopalakrishnan, B | 1 |
| Yeleswarapu, KR | 1 |
| Praveen Rao, PN | 1 |
| Amini, M | 1 |
| Li, H | 1 |
| Habeeb, AG | 1 |
| Knaus, EE | 3 |
| Byun, Y | 1 |
| Lee, KW | 1 |
| Moh, JH | 1 |
| Jeong, YS | 1 |
| Choi, YH | 1 |
| Koh, HJ | 1 |
| Park, YH | 1 |
| Oh, YI | 1 |
| Rao, PN | 2 |
| Uddin, MJ | 1 |
| Chen, QH | 1 |
| Franklin, PX | 1 |
| Pillai, AD | 1 |
| Rathod, PD | 1 |
| Yerande, S | 1 |
| Nivsarkar, M | 1 |
| Padh, H | 1 |
| Vasu, KK | 1 |
| Sudarsanam, V | 1 |
| Anzini, M | 1 |
| Rovini, M | 1 |
| Cappelli, A | 1 |
| Vomero, S | 1 |
| Manetti, F | 1 |
| Botta, M | 1 |
| Sautebin, L | 1 |
| Rossi, A | 1 |
| Pergola, C | 1 |
| Ghelardini, C | 1 |
| Norcini, M | 1 |
| Giordani, A | 1 |
| Makovec, F | 1 |
| Anzellotti, P | 1 |
| Patrignani, P | 1 |
| Biava, M | 1 |
| Tan, CM | 1 |
| Chen, GS | 1 |
| Chen, CS | 1 |
| Chang, PT | 1 |
| Chern, JW | 1 |
| Bali, A | 2 |
| Ohri, R | 1 |
| Deb, PK | 1 |
| Sharma, R | 1 |
| Chaudhari, BB | 1 |
| Kumar, R | 1 |
| Saha, N | 1 |
| Purohit, P | 1 |
| Garg, SK | 1 |
| Seth, K | 1 |
| Meena, VS | 1 |
| Dubey, S | 1 |
| Dave, K | 1 |
| Goyal, R | 1 |
| Sharma, SS | 1 |
| Banerjee, UC | 1 |
| Chakraborti, AK | 1 |
| Stricker, K | 1 |
| Yu, S | 1 |
| Krammer, G | 1 |
| Finn, A | 1 |
| Oerther, SC | 1 |
| Osterhaus, JT | 1 |
| Burke, TA | 2 |
| May, C | 1 |
| Wentworth, C | 1 |
| Whelton, A | 2 |
| Bristol, S | 1 |
| El-Shenawy, SM | 1 |
| Abdel-Salam, OM | 2 |
| Baiuomy, AR | 2 |
| El-Batran, S | 1 |
| Arbid, MS | 2 |
| White, WB | 1 |
| Bello, AE | 1 |
| Puma, JA | 1 |
| Fort, JG | 1 |
| Francischi, JN | 1 |
| Chaves, CT | 1 |
| Moura, AC | 1 |
| Lima, AS | 1 |
| Rocha, OA | 1 |
| Ferreira-Alves, DL | 1 |
| Bakhle, YS | 1 |
| Pinheiro, RM | 1 |
| Calixto, JB | 1 |
| Weaver, A | 1 |
| Alderman, M | 1 |
| Sperling, R | 1 |
| Becker, RV | 1 |
| McCoy, MA | 1 |
| Trotter, JP | 1 |
| Barbosa, AM | 1 |
| do Amaral, RO | 1 |
| Teixeira, CF | 2 |
| Hyslop, S | 1 |
| Cogo, JC | 1 |
| Baboota, S | 1 |
| Dhaliwal, M | 1 |
| Kohli, K | 1 |
| Ali, J | 1 |
| Griffin, MR | 1 |
| Stein, CM | 1 |
| Graham, DJ | 1 |
| Daugherty, JR | 1 |
| Arbogast, PG | 1 |
| Ray, WA | 1 |
| Wolfe, F | 1 |
| Zhao, S | 1 |
| Pettitt, D | 1 |
| Vajja, BN | 1 |
| Juluri, S | 1 |
| Kumari, M | 1 |
| Kole, L | 1 |
| Chakrabarti, R | 1 |
| Joshi, VD | 1 |
| Warzecha, Z | 1 |
| Dembinski, A | 1 |
| Ceranowicz, P | 1 |
| Konturek, SJ | 1 |
| Dembinski, M | 1 |
| Pawlik, WW | 1 |
| Tomaszewska, R | 1 |
| Stachura, J | 1 |
| Kusnierz-Cabala, B | 1 |
| Naskalski, JW | 1 |
| Konturek, PC | 1 |
| Liu, C | 1 |
| Desai, KG | 1 |
| Okumura, T | 2 |
| Murata, Y | 2 |
| Hizue, M | 1 |
| Matsuura, T | 1 |
| Naganeo, R | 1 |
| Kanai, Y | 1 |
| Murase, A | 2 |
| Sakakibara, A | 1 |
| Fujita, I | 1 |
| Nakao, K | 1 |
| Guindon, J | 1 |
| LoVerme, J | 1 |
| De Léan, A | 1 |
| Piomelli, D | 1 |
| Beaulieu, P | 1 |
| Valat, JP | 1 |
| Deray, G | 1 |
| Héloire, F | 1 |
| Olivo, Rdo A | 1 |
| Wallace, JL | 1 |
| Gutierrez, JM | 1 |
| Zamuner, SR | 1 |
| Feng, Y | 1 |
| Ju, H | 1 |
| Yang, B | 1 |
| An, H | 1 |
| Hau, P | 1 |
| Kunz-Schughart, L | 1 |
| Bogdahn, U | 1 |
| Baumgart, U | 1 |
| Hirschmann, B | 1 |
| Weimann, E | 1 |
| Muhleisen, H | 1 |
| Ruemmele, P | 1 |
| Steinbrecher, A | 1 |
| Reichle, A | 1 |
| Taniguchi, K | 1 |
| Nii, A | 1 |
| Boyce, S | 1 |
| Evans, J | 1 |
| Ford-Hutchinson, AW | 1 |
| Forrest, MJ | 1 |
| Gauthier, JY | 1 |
| Gresser, M | 1 |
| Kargman, S | 1 |
| Kennedy, B | 1 |
| Mancini, J | 1 |
| O'Neill, GP | 1 |
| Ouellet, M | 1 |
| Patrick, D | 1 |
| Percival, MD | 1 |
| Perrier, H | 1 |
| Rodger, I | 1 |
| Gertz, BJ | 1 |
| Krupa, D | 1 |
| Bolognese, JA | 1 |
| Sperling, RS | 1 |
| Reicin, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 6-Week Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Parallel Group Clinical Saftey Study to Evaluate Incidence of Predefined Gastrointestinal Adverse Events and Peripheral Edema in Subjects With Primary Osteoarthritis Treated W[NCT00637949] | Phase 3 | 309 participants (Actual) | Interventional | 2000-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for rofecoxib and Edema
| Article | Year |
|---|---|
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseas | 2006 |
4 trials available for rofecoxib and Edema
| Article | Year |
|---|---|
A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients.
Topics: Aged; Arthralgia; Blood Pressure; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationshi | 2008 |
Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; | 2002 |
Effects of a selective cyclooxygenase-2 inhibitor on postoperative inflammatory reaction and pain after total knee replacement.
Topics: Administration, Oral; Aged; Analgesics, Opioid; Arthritis; Arthroplasty, Replacement, Knee; Chemotax | 2008 |
Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Capecitabin | 2007 |
36 other studies available for rofecoxib and Edema
| Article | Year |
|---|---|
2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors.
Topics: Analgesics, Non-Narcotic; Animals; Arthritis, Experimental; Biological Availability; Carrageenan; Ce | 1999 |
2,2-Dimethyl-4,5-diaryl-3(2H)furanone derivatives as selective cyclo-oxygenase-2 inhibitors.
Topics: Animals; Arthritis, Experimental; Combinatorial Chemistry Techniques; Cyclooxygenase 1; Cyclooxygena | 2001 |
3,4-Diaryl-5-hydroxyfuranones: highly selective inhibitors of cyclooxygenase-2 with aqueous solubility.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Chemical Phenomena; Chemi | 2003 |
Synthesis and cyclooxygenase-2 inhibiting property of 1,5-diarylpyrazoles with substituted benzenesulfonamide moiety as pharmacophore: Preparation of sodium salt for injectable formulation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzenesulfonamides; Binding Sites; Cyclooxygenase | 2003 |
Design, synthesis, and biological evaluation of 6-substituted-3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Binding Sites; Cyclooxygenase 1; Cyclooxygenase 2; | 2003 |
In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives.
Topics: Adult; Animals; Arthritis, Experimental; Carrageenan; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxyge | 2004 |
Design, synthesis, and structure-activity relationship studies of 3,4,6-triphenylpyran-2-ones as selective cyclooxygenase-2 inhibitors.
Topics: Analgesics; Animals; Carrageenan; Cyclooxygenase 1; Cyclooxygenase 2; Edema; Isoenzymes; Membrane Pr | 2004 |
Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases.
Topics: Administration, Oral; Alkynes; Analgesics; Animals; Arachidonate 15-Lipoxygenase; Carrageenan; Cyclo | 2006 |
2-Amino-5-thiazolyl motif: a novel scaffold for designing anti-inflammatory agents of diverse structures.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Chronic Disease; Cyclooxygenase Inhib | 2008 |
Synthesis, biological evaluation, and enzyme docking simulations of 1,5-diarylpyrrole-3-alkoxyethyl ethers as selective cyclooxygenase-2 inhibitors endowed with anti-inflammatory and antinociceptive activity.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Computer Simulation; Cyclooxygenase 2 Inhibitors; Ede | 2008 |
Design, synthesis and biological evaluation of benzo[1.3.2]dithiazolium ylide 1,1-dioxide derivatives as potential dual cyclooxygenase-2/5-lipoxygenase inhibitors.
Topics: Animals; Anti-Inflammatory Agents; Arachidonate 5-Lipoxygenase; Cyclooxygenase 2; Cyclooxygenase 2 I | 2011 |
Synthesis, evaluation and docking studies on 3-alkoxy-4-methanesulfonamido acetophenone derivatives as non ulcerogenic anti-inflammatory agents.
Topics: Acetophenones; Animals; Anti-Inflammatory Agents; Carrageenan; Cyclooxygenase 2; Edema; Models, Mole | 2012 |
Synthesis of methanesulphonamido-benzimidazole derivatives as gastro-sparing antiinflammatory agents with antioxidant effect.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antioxidants; Benzimidazoles; C | 2017 |
Cyclic enaminone as new chemotype for selective cyclooxygenase-2 inhibitory, anti-inflammatory, and analgesic activities.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Carrageenan; Cyclooxygen | 2019 |
Can L(+)-lactate be used as a marker of experimentally induced inflammation in rats?
Topics: Animals; Arthritis, Experimental; Biomarkers; Carrageenan; Cyclooxygenase 2 Inhibitors; Cyclooxygena | 2010 |
Physician-reported management of edema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension.
Topics: Celecoxib; Cross-Sectional Studies; Cyclooxygenase Inhibitors; Diuretics; Edema; Humans; Hypertensio | 2002 |
Studies on the anti-inflammatory and anti-nociceptive effects of melatonin in the rat.
Topics: Administration, Topical; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; | 2002 |
Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation.
Topics: Animals; Carrageenan; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhib | 2002 |
Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation.
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Celecoxib; | 2002 |
Blood pressure control and rates of edema following the administration of the cyclooxygenase-2 specific inhibitors celecoxib versus rofecoxib in patients with systemic hypertension and osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celecoxib; Cycloox | 2003 |
A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Costs and Cost Analysis; C | 2003 |
Pharmacological characterization of mouse hind paw oedema induced by Bothrops insularis (jararaca ilhoa) snake venom.
Topics: Animals; Antivenins; Blood Proteins; Bothrops; Crotalid Venoms; Cyclooxygenase Inhibitors; Cyprohept | 2003 |
Studies on the anti-inflammatory effect of fluoxetine in the rat.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Carrageenan; Celecoxib; Cyc | 2004 |
Molecular inclusion of rofecoxib with cyclodextrin: pharmacological properties in laboratory animals.
Topics: Animals; Carrageenan; Cyclodextrins; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase I | 2004 |
High frequency of use of rofecoxib at greater than recommended doses: cause for concern.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cross-Sectional Studies | 2004 |
Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blood Pressure; Celecox | 2004 |
Lipopolysaccharide-induced paw edema model for detection of cytokine modulating anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Celecoxib; Cells, Cultured; Disease M | 2004 |
Ischemic preconditioning inhibits development of edematous cerulein-induced pancreatitis: involvement of cyclooxygenases and heat shock protein 70.
Topics: Animals; Ceruletide; Cyclooxygenase Inhibitors; Edema; HSP70 Heat-Shock Proteins; Interleukin-1; Int | 2005 |
Characteristics of rofecoxib-polyethylene glycol 4000 solid dispersions and tablets based on solid dispersions.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Calorimetry, Differential Scanning; Edema; Female; | 2005 |
Pharmacological separation between peripheral and central functions of cyclooxygenase-2 with CIAA, a novel cyclooxygenase-2 inhibitor.
Topics: Animals; Brain; Carrageenan; Celecoxib; Chlorobenzoates; Cyclooxygenase 1; Cyclooxygenase 2; Cycloox | 2006 |
Synergistic antinociceptive effects of anandamide, an endocannabinoid, and nonsteroidal anti-inflammatory drugs in peripheral tissue: a role for endogenous fatty-acid ethanolamides?
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acids; Capsaicin; Chromatography, High | 2006 |
Role of cyclooxygenases in oedema-forming activity of bothropic venoms.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents; Blotting, Western; Bothrops; Crotalid Venom | 2007 |
Effects of the selective EP4 antagonist, CJ-023,423 on chronic inflammation and bone destruction in rat adjuvant-induced arthritis.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Bone Resorption; Dinoprostone; Dose-Resp | 2008 |
Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Animals; Arachidonate 15-Lipoxygenase; Arachidonic Acid; | 1999 |
Rofecoxib for osteoarthritis and pain.
Topics: Analgesics; Cyclooxygenase Inhibitors; Diarrhea; Drug Interactions; Dyspepsia; Edema; Enzyme Inhibit | 1999 |
A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Clinical Trials, Phase II as Topic; Clinic | 2002 |